Key result
Acetaminophen is a promising alternative to indomethacin and ibuprofen for patent ductus arteriosus closure, offering comparable efficacy and a good short-term safety profile.
Why the study?
Controversy remains regarding if, when, and how to close persistent patent ductus arteriosus in premature infants.
Answers are grounded in this paper and cite their sources.
While COX inhibitors remain first-line for PDA closure, acetaminophen is emerging as a promising, lower-cost alternative with a favorable short-term safety profile.
Even though up to 60% of premature infants less than 28 weeks gestation develop persistent patent ductus arteriosus (PDA), there remains controversy regarding if, when, and how to close the PDA. Failure to close the PDA has been associated with significant morbidity but no cause-and-effect has been proven for short-term or long-term outcomes in modern times. Surgical closure has the advantage of eliminating the PDA, but short-term complications and long-term adverse outcomes are worrisome. Intravenous indomethacin has been the "gold standard" for pharmacologic treatment over the past 40 years with high closure rates and decreased incidence of severe intraventricular hemorrhage (IVH) and pulmonary hemorrhage with early treatment but without improvement in long-term outcomes and with risk of renal toxicity. Intravenous ibuprofen has less vasoconstrictive toxicity than indomethacin with comparable closure rates but without improvement in IVH and with hyperbilirubinemia risks. Earlier this decade, acetaminophen (paracetamol) was discovered to effectively close the PDA with good short-term safety profile. Although promising, acetaminophen treatment requires further studies regarding long-term safety as well as ideal dosing and route of administration.
No takes yet. Share an insight, caveat, or question.
John Ferguson (2018) conducted a review in Patent ductus arteriosus. Pharmacotherapy (indomethacin, ibuprofen, acetaminophen) was evaluated. Acetaminophen is a promising alternative to indomethacin and ibuprofen for patent ductus arteriosus closure, offering comparable efficacy and a good short-term safety profile.
Synapse has enriched 10 related papers. Consider them for comparative context: